1. Home
  2. IONS vs TX Comparison

IONS vs TX Comparison

Compare IONS & TX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IONS
  • TX
  • Stock Information
  • Founded
  • IONS 1989
  • TX 1961
  • Country
  • IONS United States
  • TX Luxembourg
  • Employees
  • IONS N/A
  • TX N/A
  • Industry
  • IONS Biotechnology: Pharmaceutical Preparations
  • TX Steel/Iron Ore
  • Sector
  • IONS Health Care
  • TX Industrials
  • Exchange
  • IONS Nasdaq
  • TX Nasdaq
  • Market Cap
  • IONS 6.0B
  • TX 6.7B
  • IPO Year
  • IONS 1991
  • TX 2006
  • Fundamental
  • Price
  • IONS $34.34
  • TX $34.17
  • Analyst Decision
  • IONS Buy
  • TX Strong Buy
  • Analyst Count
  • IONS 18
  • TX 3
  • Target Price
  • IONS $62.00
  • TX $52.33
  • AVG Volume (30 Days)
  • IONS 1.1M
  • TX 162.9K
  • Earning Date
  • IONS 11-06-2024
  • TX 11-05-2024
  • Dividend Yield
  • IONS N/A
  • TX 9.65%
  • EPS Growth
  • IONS N/A
  • TX N/A
  • EPS
  • IONS N/A
  • TX 0.40
  • Revenue
  • IONS $803,067,000.00
  • TX $18,703,544,000.00
  • Revenue This Year
  • IONS N/A
  • TX $7.13
  • Revenue Next Year
  • IONS $16.31
  • TX $2.98
  • P/E Ratio
  • IONS N/A
  • TX $84.59
  • Revenue Growth
  • IONS 30.57
  • TX 15.27
  • 52 Week Low
  • IONS $34.24
  • TX $30.68
  • 52 Week High
  • IONS $54.44
  • TX $44.44
  • Technical
  • Relative Strength Index (RSI)
  • IONS 26.91
  • TX 44.84
  • Support Level
  • IONS $37.18
  • TX $33.38
  • Resistance Level
  • IONS $40.07
  • TX $34.60
  • Average True Range (ATR)
  • IONS 1.38
  • TX 1.10
  • MACD
  • IONS -0.26
  • TX -0.12
  • Stochastic Oscillator
  • IONS 1.58
  • TX 19.51

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

About TX Ternium S.A. Ternium S.A. (each representing ten shares USD1.00 par value)

Ternium SA is a flat steel producer operating in Mexico, Brazil, Argentina, Colombia, the southern United States, and Central America. It produces finished and semi-finished steel products and iron ore, which are sold either directly to steel manufacturers and steel processors or end-users. The company operates in two segments: Steel, Usiminas and Mining. In its steel segment, the company produces slabs, billets & round bars, hot-rolled coils & sheets, bars & stirrups, wire rods, steel pipes, and other products. The Mining segment sells iron ore as concentrates (fines) and pellets. The Usiminas segment include iron ore extraction, steel transformation, production of capital goods and logistics. The vast majority of its revenue comes from the steel segment and geographically from Mexico.

Share on Social Networks: